Medicenna Therapeutics Selects Kalon Biotherapeutics To Manufacture New Cancer Drug

Published on: 

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-07-02-2014, Volume 10, Issue 7

Medicenna Therapeutics selects Kalon Biotherapeutics to manufacture a new brain cancer drug for children and adults.

Medicenna Therapeutics, a clinical stage immune-oncology company, has selected Kalon Biotherapeutics, an advanced biologics contract development and manufacturing company, to manufacture materials that will accelerate the development, testing, and Phase 3/commercialization of several new cancer drugs in the pipeline. The operations of Kalon Biotherapeutics are located in the National Center for Therapeutics Manufacturing on the campus of Texas A&M in College Station, Texas.

Kalon’s first project with Medicenna is for a clinical trial testing the effectiveness of Medicenna’s empowered cytokines (ECs) for children with brain cancer. The agreement provides for Kalon to manufacture the material that will be used in human clinical trials in children and adults with brain cancer.


Source: Kalon Biotherapeutics